Title: Analyzing NAFLD Interventional Clinical Trial Registration Based on the
ClinicalTrials.gov Database
Version: 2 Date: 26 Jan 2025
Reviewer's report:
This study provides an overview of the MASLD/NAFLD interventional clinical trials. However,
I have concerns about the conduct and decisions that need further clarification:
Key points:
1. Please use current terminology (i.e., MASLD) consistently throughout the manuscript.
2. Provide more detailed information on the methodology, including the full search strategy,
data handling (how? who? what was done?), and statistical analysis.
3. The authors show the global distribution of MASLD clinical trials. However, it is unclear
whether this distribution includes multinational trials, leading to uncertainty as to whether
this information is accurate. For example, there are MASH trials with sites in Argentina
(NCT03053050, NCT03205150, NCT02855164, NCT03517540), which is shown as having
0 trials. Please investigate the multinational trials further or clearly state that the countries
considered are only those registered in the CT.gov database and acknowledge this as a limitation.
In addition, a table showing the number of trials for each country and their further stratification
by income level (according to the World Bank country classification) would be welcome.
4. Please clarify why phases of studies were classified as 'NA' (not applicable).
Minor points:
1. Introduction: Please provide information on the prevalence of MASLD with updated data
(PMID: 36626630).
Title: Analyzing NAFLD Interventional Clinical Trial Registration Based on the
ClinicalTrials.gov Database
Version: 2 Date: 26 Jan 2025
Reviewer's report:
This study provides an overview of the MASLD/NAFLD interventional clinical trials. However,
I have concerns about the conduct and decisions that need further clarification:
Key points:
1. Please use current terminology (i.e., MASLD) consistently throughout the manuscript.
2. Provide more detailed information on the methodology, including the full search strategy,
data handling (how? who? what was done?), and statistical analysis.
3. The authors show the global distribution of MASLD clinical trials. However, it is unclear
whether this distribution includes multinational trials, leading to uncertainty as to whether
this information is accurate. For example, there are MASH trials with sites in Argentina
(NCT03053050, NCT03205150, NCT02855164, NCT03517540), which is shown as having
0 trials. Please investigate the multinational trials further or clearly state that the countries
considered are only those registered in the CT.gov database and acknowledge this as a limitation.
In addition, a table showing the number of trials for each country and their further stratification
by income level (according to the World Bank country classification) would be welcome.
4. Please clarify why phases of studies were classified as 'NA' (not applicable).
Minor points:
1. Introduction: Please provide information on the prevalence of MASLD with updated data
(PMID: 36626630).
Please review this paper.
user
Title: Analyzing NAFLD Interventional Clinical Trial Registration Based on the
ClinicalTrials.gov Database
Version: 2 Date: 26 Jan 2025
Reviewer's report:
This study provides an overview of the MASLD/NAFLD interventional clinical trials. However,
I have concerns about the conduct and decisions that need further clarification:
Key points:
1. Please use current terminology (i.e., MASLD) consistently throughout the manuscript.
2. Provide more detailed information on the methodology, including the full search strategy,
data handling (how? who? what was done?), and statistical analysis.
3. The authors show the global distribution of MASLD clinical trials. However, it is unclear
whether this distribution includes multinational trials, leading to uncertainty as to whether
this information is accurate. For example, there are MASH trials with sites in Argentina
(NCT03053050, NCT03205150, NCT02855164, NCT03517540), which is shown as having
0 trials. Please investigate the multinational trials further or clearly state that the countries
considered are only those registered in the CT.gov database and acknowledge this as a limitation.
In addition, a table showing the number of trials for each country and their further stratification
by income level (according to the World Bank country classification) would be welcome.
4. Please clarify why phases of studies were classified as 'NA' (not applicable).
Minor points:
1. Introduction: Please provide information on the prevalence of MASLD with updated data
(PMID: 36626630).
assistant